Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily L Days

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Neurobiology|November 20, 2004
Age-related loss of neuronal nicotinic receptor expression in the aging mouse hippocampus corresponds with cyclooxygenase-2 and PPAR gamma expression and is altered by long-term NS398 administrationLorise C Gahring, Karina Persiyanov, Emily L Days, et al.
American Journal of Physiology. Cell Physiology|May 16, 2026
Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state‑dependent inactivator preferentially active against pathogenic gain‑of‑function mutantsRahul U Chandrappa, Vaishali Satpute Janve, Emily L Days, et al.
Plos One|March 31, 2017
Screening for AMPA receptor auxiliary subunit specific modulatorsCaleigh M Azumaya, Emily L Days, Paige N Vinson, et al.
Journal of Biomolecular Screening|February 15, 2014
A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon ReceptorsLindsey C Morris, Emily L Days, Maxine Turney, et al.
Journal of Neuroimmunology|July 19, 2005
Pro-inflammatory cytokines modify neuronal nicotinic acetylcholine receptor assemblyLorise C Gahring, Emily L Days, Tuesday Kaasch, et al.
American Journal of Physiology. Cell Physiology|February 11, 2026
Activation of TMEM175 lysosomal ion channels by CysLT1 receptor antagonistsKangjun Li, Vaishali Satpute Janve, Samantha D Le, et al.
Molecular Pharmacology|February 1, 2024
Discovery and Characterization of VU0542270, the First Selective Inhibitor of Vascular Kir6.1/SUR2B K<sub>ATP</sub> ChannelsKangjun Li, Samantha J McClenahan, Changho Han, et al.
Journal of Medicinal Chemistry|January 20, 2017
Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione CoreKellie D Nance, Emily L Days, C David Weaver, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Assay and Drug Development Technologies|February 17, 2026
Identification of Kir2.1 Inhibitors from a High-Throughput ScreenJacob L Bouchard, Pedro de Andrade Horn, Yu Nishio, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Neurobiology|November 20, 2004
Age-related loss of neuronal nicotinic receptor expression in the aging mouse hippocampus corresponds with cyclooxygenase-2 and PPAR gamma expression and is altered by long-term NS398 administrationLorise C Gahring, Karina Persiyanov, Emily L Days, et al.
American Journal of Physiology. Cell Physiology|May 16, 2026
Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state‑dependent inactivator preferentially active against pathogenic gain‑of‑function mutantsRahul U Chandrappa, Vaishali Satpute Janve, Emily L Days, et al.
Plos One|March 31, 2017
Screening for AMPA receptor auxiliary subunit specific modulatorsCaleigh M Azumaya, Emily L Days, Paige N Vinson, et al.
Journal of Biomolecular Screening|February 15, 2014
A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon ReceptorsLindsey C Morris, Emily L Days, Maxine Turney, et al.
Journal of Neuroimmunology|July 19, 2005
Pro-inflammatory cytokines modify neuronal nicotinic acetylcholine receptor assemblyLorise C Gahring, Emily L Days, Tuesday Kaasch, et al.
American Journal of Physiology. Cell Physiology|February 11, 2026
Activation of TMEM175 lysosomal ion channels by CysLT1 receptor antagonistsKangjun Li, Vaishali Satpute Janve, Samantha D Le, et al.
Molecular Pharmacology|February 1, 2024
Discovery and Characterization of VU0542270, the First Selective Inhibitor of Vascular Kir6.1/SUR2B K<sub>ATP</sub> ChannelsKangjun Li, Samantha J McClenahan, Changho Han, et al.
Journal of Medicinal Chemistry|January 20, 2017
Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione CoreKellie D Nance, Emily L Days, C David Weaver, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Assay and Drug Development Technologies|February 17, 2026
Identification of Kir2.1 Inhibitors from a High-Throughput ScreenJacob L Bouchard, Pedro de Andrade Horn, Yu Nishio, et al.
Pageof 3